We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

47 hedge funds and large institutions have $124M invested in NKGen Biotech, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

7% more funds holding

Funds holding: 44 → 47 (+3)

3% more capital invested

Capital invested by funds: $120M → $124M (+$3.55M)

Holders
47
Holders Change
+3
Holders Change %
+6.82%
% of All Funds
0.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CSS
Cubist Systematic Strategies
Connecticut
+$3.23M
2
CF
Cantor Fitzgerald
New York
+$2.48M
3
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$1.6M
4
EAM
Exos Asset Management
New York
+$700K
5
MF
Magnetar Financial
Illinois
+$612K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$3.39M
2
SG
StoneX Group
New York
-$97K
3
HighTower Advisors
HighTower Advisors
Illinois
-$3.16K

NKGN Hedge Fund Activity: Q2 2022 in Review

47 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2022, worth a combined $124M — up 3% from $120M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NKGN positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Cubist Systematic Strategies, adding an estimated $3.23M. The largest seller was Bank of America, exiting entirely with an estimated $3.39M sold.

  • 47 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2022, up from 44 in Q1 2022.
  • Funds reported $124M of NKGen Biotech, Inc. Common Stock stock for Q2 2022, up 3% quarter-over-quarter.
  • 7 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2022 and 3 closed out, a net change of +4 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q2 2022 was Cubist Systematic Strategies, an estimated $3.23M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q2 2022 was Bank of America, an estimated $3.39M sold.

Based on aggregated 13F filings for Q2 2022.